Blueprint Medicines Corpo... (BPMC)
Blueprint Medicines Statistics
Share Statistics
Blueprint Medicines has 63.91M shares outstanding. The number of shares has increased by 3.75% in one year.
| Shares Outstanding | 63.91M |
| Shares Change (YoY) | 3.75% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 62.64M |
| Failed to Deliver (FTD) Shares | 43 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 5.14M, so 8.09% of the outstanding shares have been sold short.
| Short Interest | 5.14M |
| Short % of Shares Out | 8.09% |
| Short % of Float | 8.26% |
| Short Ratio (days to cover) | 6.49 |
Valuation Ratios
The PE ratio is -81.72 and the forward PE ratio is -122.47. Blueprint Medicines's PEG ratio is 0.94.
| PE Ratio | -81.72 |
| Forward PE | -122.47 |
| PS Ratio | 10.77 |
| Forward PS | 3.3 |
| PB Ratio | 18.36 |
| P/FCF Ratio | -27.8 |
| PEG Ratio | 0.94 |
Enterprise Valuation
Blueprint Medicines Corporation has an Enterprise Value (EV) of 6.29B.
| EV / Earnings | -93.74 |
| EV / Sales | 12.36 |
| EV / EBITDA | -29.66 |
| EV / EBIT | -29.66 |
| EV / FCF | -31.89 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.85 |
| Quick Ratio | 2.8 |
| Debt / Equity | 0.42 |
| Total Debt / Capitalization | 29.68 |
| Cash Flow / Debt | -1.53 |
| Interest Coverage | -3.08 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -50.86%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.06% |
| Return on Capital (ROIC) | -50.86% |
| Revenue Per Employee | $784,012.33 |
| Profits Per Employee | $-103,372.88 |
| Employee Count | 649 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | 1.23M |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -6.5% in the last 52 weeks. The beta is 0.57, so Blueprint Medicines's price volatility has been higher than the market average.
| Beta | 0.57 |
| 52-Week Price Change | -6.5% |
| 50-Day Moving Average | 98.32 |
| 200-Day Moving Average | 96.8 |
| Relative Strength Index (RSI) | 43.4 |
| Average Volume (20 Days) | 997.36K |
Income Statement
In the last 12 months, Blueprint Medicines had revenue of 508.82M and earned -67.09M in profits. Earnings per share was -1.07.
| Revenue | 508.82M |
| Gross Profit | 488.66M |
| Operating Income | -212.04M |
| Net Income | -67.09M |
| EBITDA | -212.04M |
| EBIT | -212.04M |
| Earnings Per Share (EPS) | -1.07 |
Balance Sheet
The company has 102.01M in cash and 126.05M in debt, giving a net cash position of -24.04M.
| Cash & Cash Equivalents | 102.01M |
| Total Debt | 126.05M |
| Net Cash | -24.04M |
| Retained Earnings | -2.41B |
| Total Assets | 1.18B |
| Working Capital | 481.88M |
Cash Flow
In the last 12 months, operating cash flow was -192.59M and capital expenditures -4.63M, giving a free cash flow of -197.22M.
| Operating Cash Flow | -192.59M |
| Capital Expenditures | -4.63M |
| Free Cash Flow | -197.22M |
| FCF Per Share | -3.14 |
Margins
Gross margin is 96.04%, with operating and profit margins of -41.67% and -13.19%.
| Gross Margin | 96.04% |
| Operating Margin | -41.67% |
| Pretax Margin | -12.94% |
| Profit Margin | -13.19% |
| EBITDA Margin | -41.67% |
| EBIT Margin | -41.67% |
| FCF Margin | -38.76% |
Dividends & Yields
BPMC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.21% |
| FCF Yield | -3.48% |
Analyst Forecast
The average price target for BPMC is $126, which is 42.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $126 |
| Price Target Difference | 42.1% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
Scores
| Altman Z-Score | 1.51 |
| Piotroski F-Score | 2 |